INTRODUCTION
Now that overall event-free survival rates for paediatric acute lymphoblastic leukaemia (ALL) are approaching 75-80%, there would seem to be little justification for high dose chemo-radiotherapy and stem cell rescue (BMT) for children in first remission. Yet these excellent overall figures mask significant discrepancies in clinical outcome.
Identification of Highest Risk Patients with ALL
An early attempt to identify prognostic features in ALL based on age and Leukocyte count (1) has been more recently refined (2). Despite a lack of international consensus on risk assessment in ALL (3) these clinical features, in combination with therapy response and biological characteristics, can be used to stratify patients into risk groups (Table 1) .
Two-thirds of all children, stratified as standard risk on the basis of age and Leukocyte count have an excellent chance of cure after treatment with induction, intensification, CNS-directed treatment and continuing (maintenance) therapy. A small minority of these may be reassigned as highest risk on the basis of poor treatment response or adverse cytogenetics (see below).
Children in the higher risk group, often selected on the basis of age and Leukocyte count respond well to intensified chemotherapy (3,4) and even those with a poor initial response to treatment, judged by bone marrow examination after seven days of therapy, may achieve prolonged remission after intensified induction and reconsolidation therapy (5) . Remaining questions about therapy in the higher risk group include: refinement of chemotherapy, identifying the likely treatment failures, possibly by measurement of minimal residual disease and clarification around the need for cranial irradiation (3). The 1-2% of children with surface membrane immunoglobulin positive B-ALL are now highly curable with short term intensive chemotherapy (6) and form a "special" rather than highest risk group.
There remains 8-9% of children, in whom the expected event-free survival is under 40%. Some of these (Table 2 ) may be identified on the basis of clinical features and/or biology, although there is no consensus about the prognostic significance of all these features. Failure to achieve remission after four weeks of induction therapy (7, 8) , is always associated with a poor prognosis. Infants under one year form a heterogeneous group, including some with CD10 positive pre-B ALL, but the majority, with high Leukocyte counts, organomegaly and translocations involving the MLL gene, are at high risk of relapse even after intensive therapy (9) . The event free survival in two consecutive series of infants treated by the Children's Cancer Group was 33% and 39 % at four years (10) .
A recent international study of Philadelphiachromosome (Ph 1 ) positive leukaemia showed that overall long term EFS was poor -25% at seven years. Some patients with favourable clinical prognostic features responded to intensive chemotherapy but overall, in this retrospective survey, BMT from histocompatible sibling was superior to other types of treatment (11) . There is little debate about the poor prognosis of the rare near-haploid ALL but the report that ALL in association with less than 45 chromosomes is associated with a poor prognosis (12) has not been confirmed by other groups.
Chemotherapy in Highest Risk Patients
Some published results of chemotherapy in highest risk patients are illustrated in Table 3 . These patients have not all been selected on biological criteria and are a heterogeneous group, including some children who are older, have T-ALL and / or a high Leukocyte count, in addition to those with cytogenetic abnormalities, such as Ph 1 . Overall the reported event-free survival with chemotherapy is of the order of 30-40%.
Evaluation of BMT in first remission
There has always been reluctance in ALL, in contrast to AML, to recommend or to evaluate high dose therapy and BMT in first remission. This is partly because the overall results in ALL have historically been superior, but also because of a "wait and see" attitude with the concept that BMT can be used as second line treatment for children who fail therapy in first remission. The main problem of this approach for highest risk children, who tend to relapse early, is that second remissions in this population tend to be very unstable, and that BMT like other forms of treatment, is associated with a high risk of subsequent relapse.
For example, in an unselected population of all children relapsing after the MRC UKALL X trial , only 3% of 106 children with a bone marrow or combined relapse within two years of diagnosis remained alive in second remission, despite further intensive chemotherapy or BMT (17) .
The evaluation of BMT in first remission of ALL, as in other diseases, is fraught with logistic and statistical problems. Many small reports come from transplant centres and have no comparable group of patients receiving chemotherapy. The inherent delays in time to transplant may introduce bias. The selection criteria for BMT are inconstant, and often include a mixture of biological and clinical variables. It is impossible to perform randomised trials of BMT and this leads to selection bias, which may be partly overcome by comparing outcome by donor availability rather than actual treatment.
Comparative Studies of BMT and chemotherapy
Most of these studies have been relatively small and retrospective. A Scandinavian case-control study compared 22 patients receiving sibling BMT with 44 closely matched controls (18) and an Italian study compared 30 children receiving BMT with 130 matched controls with similar clinical features (19) . Both reports concluded that BMT reduced the risk of relapse.
A recent large American study has compared the outcome for 201 patients who received BMT in first remission ALL and reported to the IBMTR with 683 case matched controls treated by the paediatric oncology group. The definition of very high risk ALL was based on age, Leukocyte count and immunophenotype and patients with Ph 1 positive ALL and t (4;11) were excluded. At ten years of follow up the group of patients with non T-ALL who received BMT had a significant difference in leukaemiafree survival (39% cf 58%), but no difference in overall survival (55% vs 61%). The group with T-ALL showed no significant difference in LFS between chemotherapy (53%) and BMT (63%) and no difference in survival (20) .
In the UK we have tried to compare BMT and chemotherapy prospectively in MRC UKALL X (21) , and the successor trial UKALL XI, a similar protocol. The results, recently updated (22) , compared the outcome of BMT and chemotherapy in a group of highest risk children aged 1-15 treated on the two trials. The highest risk group comprised 13% of the total population. The initial plan was to confine BMT to children with a histocompatible sibling donor, but while only 76 of the 99 children with a donor proceeded to BMT an additional 25 received BMT from a matched unrelated donor. The median time to transplant was five months.
The results comparing children who received either family or unrelated donor transplants are shown in Table 4 . Results are shown both unadjusted and after allowing for time to transplant, Leukocyte count, Ph 1 chromosome and ploidy. It can be seen that there was a highly significant increase in treatment related deaths in the transplant group and a significant decrease in relapses in the transplant group. The net result was that there was no benefit overall for BMT.
In order to avoid bias the results were also analysed according to the availability of a histocompatible sibling donor and these are shown in Table 5 . Again, sibling donor availability was associated with an increased risk of remission death, but and no overall benefit. The results were not influenced by censoring the children who received unrelated donor transplants.
Thus in this relatively large series of patients any possible decrease in relapse rate was outweighed by the increased transplant related mortality.
In conclusion, there is no evidence at present that BMT is superior to conventional treatment in the broad group of children with highest risk ALL. There may, however be a case, for prospective evaluation of BMT in clearly defined subsets of patients.
BMT for Selected Highest Risk Groups
Patients who do not achieve haematological remission at 28 days are a heterogeneous group, including some with classic high risk features or adverse cytogenetics. Their prognosis is poor but they may achieve leukaemia free survival with BMT (23) and delayed remission should be considered as an indication.
The most distinct group of highest risk children are those with Ph 1 postive leukaemia. The recent large multinational retrospective study (11) showed that only BMT from a family matched donor was superior to chemotherapy. In view of the poor prognosis of Ph 1 ALL and recent more encouraging reports of successful UDBMT (24, 25) this option should be considered for children with Ph 1 positive ALL in first remission.
There is uniform agreement about the poor prognosis of many infants with ALL especially those with MLL gene rearrangement (26) , or a poor response to steroids before induction (27) . There are few reports of BMT in remission for infants and continuing uncertainty about the best preparative regimen. A small series from Chicago involved seven infants who received etoposide, and cyclophosphamide and also TBI (28) , with four survivors. Many investigators would be reluctant to use TBI in this age group. More recently 41 infants with ALL have received unrelated donor cord blood transplants, 21 in first remission with an EFS of 65% at 2 years (29) .
At present in the new international infant protocol it is proposed that BMT be evaluated for children with a poor steroid response. The significance of MLL gene rearrangement in older children remains controversial but there is some evidence that children aged 2-9 and t (4;11) may not have the poor prognosis of older and younger children (30) .
CONCLUSIONS
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